C9RAN translation

A potential therapeutic target for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

A hexanucleotide (GGGGCC) repeat expansion within a non-coding region of the C9ORF72 gene is the most common mutation associated with both frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Elucidating how these expanded repeats (GGGGCCexp) cause 'c9FTD/ALS' has since become an important goal of the FTD/ALS field. GGGGCCexp transcripts aggregate into discrete nuclear structures, termed RNA foci. This phenomenon, observed in various repeat expansion disorders, is associated with RNA-binding protein sequestration. Of note, recent findings show that GGGGCCexp transcripts also succumb to an alternative fate: repeat-associated non-ATG translation (RAN translation). This unconventional mode of translation, which occurs in the absence of an initiating codon, results in the production of polyGA, polyGP and polyGR peptides. Antibodies generated against these peptides detect high molecular weight, insoluble material in brain homogenates, as well as neuronal inclusions throughout the central nervous system of c9FTD/ALS cases. Given that both foci formation and RAN translation in c9FTD/ALS require the synthesis of GGGGCCexp RNA, therapeutic strategies that target these transcripts and result in their neutralization or degradation could effectively block these two potential pathogenic mechanisms and provide a much needed treatment for c9FTD/ALS.

Original languageEnglish (US)
Pages (from-to)991-995
Number of pages5
JournalExpert Opinion on Therapeutic Targets
Volume17
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Amyotrophic Lateral Sclerosis
RNA
Peptides
RNA-Binding Proteins
Neurology
Brain
Genes
Molecular weight
Degradation
Antibodies
Therapeutics
Codon
Central Nervous System
Molecular Weight
Mutation
Frontotemporal Dementia With Motor Neuron Disease

Keywords

  • Amyotrophic lateral sclerosis
  • C9ORF72
  • Expanded hexanucleotide repeat
  • Foci
  • Frontotemporal dementia
  • Neurodegeneration
  • Repeat-associated non-ATG translation
  • RNA

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

@article{b11c3725f6fa43089f79bd88d3e3d662,
title = "C9RAN translation: A potential therapeutic target for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia",
abstract = "A hexanucleotide (GGGGCC) repeat expansion within a non-coding region of the C9ORF72 gene is the most common mutation associated with both frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Elucidating how these expanded repeats (GGGGCCexp) cause 'c9FTD/ALS' has since become an important goal of the FTD/ALS field. GGGGCCexp transcripts aggregate into discrete nuclear structures, termed RNA foci. This phenomenon, observed in various repeat expansion disorders, is associated with RNA-binding protein sequestration. Of note, recent findings show that GGGGCCexp transcripts also succumb to an alternative fate: repeat-associated non-ATG translation (RAN translation). This unconventional mode of translation, which occurs in the absence of an initiating codon, results in the production of polyGA, polyGP and polyGR peptides. Antibodies generated against these peptides detect high molecular weight, insoluble material in brain homogenates, as well as neuronal inclusions throughout the central nervous system of c9FTD/ALS cases. Given that both foci formation and RAN translation in c9FTD/ALS require the synthesis of GGGGCCexp RNA, therapeutic strategies that target these transcripts and result in their neutralization or degradation could effectively block these two potential pathogenic mechanisms and provide a much needed treatment for c9FTD/ALS.",
keywords = "Amyotrophic lateral sclerosis, C9ORF72, Expanded hexanucleotide repeat, Foci, Frontotemporal dementia, Neurodegeneration, Repeat-associated non-ATG translation, RNA",
author = "Gendron, {Tania D} and Cosio, {Danielle M.} and Leonard Petrucelli",
year = "2013",
month = "9",
doi = "10.1517/14728222.2013.818659",
language = "English (US)",
volume = "17",
pages = "991--995",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - C9RAN translation

T2 - A potential therapeutic target for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia

AU - Gendron, Tania D

AU - Cosio, Danielle M.

AU - Petrucelli, Leonard

PY - 2013/9

Y1 - 2013/9

N2 - A hexanucleotide (GGGGCC) repeat expansion within a non-coding region of the C9ORF72 gene is the most common mutation associated with both frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Elucidating how these expanded repeats (GGGGCCexp) cause 'c9FTD/ALS' has since become an important goal of the FTD/ALS field. GGGGCCexp transcripts aggregate into discrete nuclear structures, termed RNA foci. This phenomenon, observed in various repeat expansion disorders, is associated with RNA-binding protein sequestration. Of note, recent findings show that GGGGCCexp transcripts also succumb to an alternative fate: repeat-associated non-ATG translation (RAN translation). This unconventional mode of translation, which occurs in the absence of an initiating codon, results in the production of polyGA, polyGP and polyGR peptides. Antibodies generated against these peptides detect high molecular weight, insoluble material in brain homogenates, as well as neuronal inclusions throughout the central nervous system of c9FTD/ALS cases. Given that both foci formation and RAN translation in c9FTD/ALS require the synthesis of GGGGCCexp RNA, therapeutic strategies that target these transcripts and result in their neutralization or degradation could effectively block these two potential pathogenic mechanisms and provide a much needed treatment for c9FTD/ALS.

AB - A hexanucleotide (GGGGCC) repeat expansion within a non-coding region of the C9ORF72 gene is the most common mutation associated with both frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Elucidating how these expanded repeats (GGGGCCexp) cause 'c9FTD/ALS' has since become an important goal of the FTD/ALS field. GGGGCCexp transcripts aggregate into discrete nuclear structures, termed RNA foci. This phenomenon, observed in various repeat expansion disorders, is associated with RNA-binding protein sequestration. Of note, recent findings show that GGGGCCexp transcripts also succumb to an alternative fate: repeat-associated non-ATG translation (RAN translation). This unconventional mode of translation, which occurs in the absence of an initiating codon, results in the production of polyGA, polyGP and polyGR peptides. Antibodies generated against these peptides detect high molecular weight, insoluble material in brain homogenates, as well as neuronal inclusions throughout the central nervous system of c9FTD/ALS cases. Given that both foci formation and RAN translation in c9FTD/ALS require the synthesis of GGGGCCexp RNA, therapeutic strategies that target these transcripts and result in their neutralization or degradation could effectively block these two potential pathogenic mechanisms and provide a much needed treatment for c9FTD/ALS.

KW - Amyotrophic lateral sclerosis

KW - C9ORF72

KW - Expanded hexanucleotide repeat

KW - Foci

KW - Frontotemporal dementia

KW - Neurodegeneration

KW - Repeat-associated non-ATG translation

KW - RNA

UR - http://www.scopus.com/inward/record.url?scp=84882687005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882687005&partnerID=8YFLogxK

U2 - 10.1517/14728222.2013.818659

DO - 10.1517/14728222.2013.818659

M3 - Article

VL - 17

SP - 991

EP - 995

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 9

ER -